Thursday, Kyverna Therapeutics, Inc. (KYTX) announced that the FDA has approved its Investigational New Drug or IND application for KYV-101. This clearance allows the utilization of KYV-101 in the treatment of stiff-person syndrome in Kyverna's Phase 2, open-label KYSA-8 clinical trial.
KYV-101 is a fully human anti-CD19 CAR T-cell product designed for patients with B-cell-driven autoimmune diseases. It is currently under evaluation in sponsored, open-label Phase 1/2 and Phase 2 trials for rheumatology and neurology.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.